Kineesiotaping for Patients With LCPD

April 21, 2023 updated by: Sezen Karaborklu Argut, Istanbul University - Cerrahpasa (IUC)

Effects of Kinesiotaping in Patients With Legg-Calvé-Perthes Disease: A Randomized, Double-blind, Placebo-controlled Trial

Kinesiotaping is increasingly being used as a complement to musculoskeletal pain management. This study aimed to evaluate the immediate clinical efficacy of kinesiotaping on pain and pain-related symptoms of Legg-Calvé-Perthes Disease (LCPD).

Study Overview

Status

Completed

Detailed Description

Kinesio taping is increasingly being used as a complement to musculoskeletal pain management. A randomized, double-blind, placebo-controlled clinical trial was conducted. Activity-related hip pain, passive and pain limited hip range of motion, gluteus medius muscle strength, function and balance were assessed.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • Istanbul University-Cerrahpasa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Having received unilateral LCPD diagnosis,
  • Anterior hip pain minimum three points on 10-cm Visual Analog Scale (VAS) over the previous week,
  • Having the following symptoms; weakness of gluteus medius muscle and patient-reported complaints on function or balance

Exclusion Criteria:

  • Having a history of any other hip pathologies,
  • Having allergy to polyacrylate adhesive,
  • Having used analgesic medication within the previous three days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Kinesiotaping group
Kinesiotape was applied to the lateral side of the affected hip for gluteus medius muscle. Each patient was positioned lying down with the affected side up, and two I-strips were used.

Two I-strips were used:

  1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.
  2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.
Sham Comparator: Sham taping group
Sham tape was applied with a single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the affected hip.
A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immediate Clinical Efficacy on Activity Related Hip
Time Frame: The change between T1 (baseline) to T2 (thirty minutes later from the application)
Horizontal 10 cm VAS (0, no pain; 10, the worst pain ever possible)
The change between T1 (baseline) to T2 (thirty minutes later from the application)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immediate Clinical Efficacy on Hip Abduction ROM
Time Frame: The change between T1 (baseline) to T2 (thirty minutes later from the application)
goniometric range of motion (ROM)
The change between T1 (baseline) to T2 (thirty minutes later from the application)
Immediate Clinical Efficacy on Functional Task Durations
Time Frame: The change between T1 (baseline) to T2 (thirty minutes later from the application)
10-meters walk task duration (sec) and 10-step climbing task duration (sec)
The change between T1 (baseline) to T2 (thirty minutes later from the application)
Immediate Clinical Efficacy on Balance test durations
Time Frame: The change between T1 (baseline) to T2 (thirty minutes later from the application)
One leg stance test duration (sec) and Tandem walk test duration (sec)
The change between T1 (baseline) to T2 (thirty minutes later from the application)
Immediate Clinical Efficacy on Gluteus medius muscle strength
Time Frame: The change between T1 (baseline) to T2 (thirty minutes later from the application)
muscle strength by handheld dynamometer (Ibs)
The change between T1 (baseline) to T2 (thirty minutes later from the application)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 25, 2017

Primary Completion (Actual)

April 6, 2020

Study Completion (Actual)

January 11, 2021

Study Registration Dates

First Submitted

March 20, 2023

First Submitted That Met QC Criteria

April 21, 2023

First Posted (Actual)

May 3, 2023

Study Record Updates

Last Update Posted (Actual)

May 3, 2023

Last Update Submitted That Met QC Criteria

April 21, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Legg-Calve-Perthes Disease

Clinical Trials on Kinesiotaping

3
Subscribe